Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px
Document › Details

Medigene AG. (2/2/17). "Press Release: Medigene Participates at Five National and International Conferences in February and March 2017". Martinsried.

Organisations Organisation Medigene AG (MDG1, Frankfurt, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Biotech and Money (GB)
Products Product Biotech and Money 2017 London
  Product 2 T cell therapy
Persons Person Taapken, Thomas (Medigene 201701– CFO before Epigenomics + Biotie/elbion + DVC + Burrill + Hoechst)
  Person 2 Mayer, Robert (Medigene 201512– Senior Manager PR + IR before College Hill Life Sciences/Northbank Munich)
     


Medigene AG (FSE: MDG1, Prime Standard) announces its participation at five upcoming scientific, investor and business development conferences:

* Biotech and Money London
Date: 07 - 08 February 2017
Location: London, UK
Dr. Thomas Taapken, Medigene's CFO, will give a corporate presentation on 8th February at 9.25 am.

* ODDO 11th German Conference
Date: 15 - 16 February 2017
Location: Frankfurt, Germany

* International Symposium ACUTE LEUKEMIAS XVI
Date: 19 - 22 February 2017
Location: Munich, Germany

* 9th International Cellular Therapy Symposium
Date: 16 -17 March 2017
Location: Erlangen, Germany

* BIO-Europe Spring
Date: 20 - 23 March 2017
Location: Barcelona, Spain


Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit http://medigene.com


This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

   
Record changed: 2017-07-02

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px